In 2023, the Hong Kong stock market's 18A segment celebrated its fifth year of listing, and the fifth set of standards for the Sci-tech Innovation Board welcomed its fourth year of operation. A total of 85 biotech companies have successfully gone public through this listing channel, driving the entire life science sector into high gear. Having experienced a boom and pursuit, as well as a cold winter and rationality, life science companies have never stopped innovating and breaking through. They continuously inject development momentum through technological innovation and bridge gaps through business model innovation. After experiencing dark moments, they still see themselves standing at a new starting point and forging ahead.
From September 27th to 28th, Frost & Sullivan (Frost & Sullivan, abbreviated as: F&S) will grandly host its second New Investment Expo and the 17th Frost & Sullivan Global Growth, Sci-tech Innovation and Leadership Summit (abbreviated as "F&S New Investment Conference"), at the Shangri-La Hotel in Pudong, Shanghai. The conference will prominently launchthe New Life Science Investment Summit Forumwith the theme of“New Directions for the Future & Forging Ahead”bringing togetherindustry leaders, life science companies, investment institutions, and professional service providersto focus on new opportunities in life science investment and financing, and jointly discuss the capital and industrial forces for companies to navigate cycles.
We sincerely invite you to attend this forum and embark on a successful journey towards the capital market of life science companies!
Date:September 27th - 28th, 2023
Venue:Shangri-La Hotel in Pudong, Shanghai
Sponsors:Frost & Sullivan, China Biomedical Industry Chain Innovation and Transformation Alliance (CBIITA)
About Hexun Biotech
Hexun Biotechnology (Shanghai) Co., Ltd. (Stock Code: 688238) was established in 2013 and is a biotech company focusing on the field of gene therapy. It specializes in providing CRO services such as the development of gene therapy vectors, gene function research, drug targets, and pharmacodynamic studies for basic research on gene therapy, as well as CDMO services such as process development and testing, IND-CMC pharmacology research, and clinical sample GMP production for the research and development of gene drugs.
The company takes "Empowering Gene Therapy, Jointly Guarding Life and Health" as its mission. Centering on the research and development of viral vectors and large-scale production processes, it has built two core technology clusters: gene therapy vector production process and quality control technology. It has established a large-scale and highly flexible GMP production system suitable for various gene drugs, providing services such as: ① vector products such as plasmids, adeno-associated viruses, and lentiviruses; ② various oncolytic herpes viruses and oncolytic poxviruses; ③ cell therapy products such as CAR-T and CAR-NK; ④ other products such as mRNA, including technical research, process development, and GMP production services.
Based on the comprehensive technical platforms independently built by the company, including a molecular biology platform, an experimental-grade viral vector packaging platform, a cell function research platform, a SPF-level animal experiment platform, a clinical-level gene therapy vector and cell therapy process development platform, and a quality control technology research platform, relying on the company's existing nearly 5,000 square meters of R&D center, over 10,000 square meters of GMP production center for gene therapy vectors, and a 77,000 square meters precision medicine industry base in the Lingang New Area of the Shanghai Pilot Free Trade Zone, the company will adhere to a customer-centered approach and take providing professional services as its own responsibility, aiming to build an internationally leading CXO group enterprise in gene and cell therapy, accelerating the basic research, drug discovery, pharmacology research, clinical, and commercialization processes of gene therapy, promoting the development of the gene therapy industry, and benefiting human health.
Introduction to Speakers
Jia Guodong, CEO of Hexun Biotechnology (Shanghai) Co., Ltd. (Stock Code: 688238), led the company's listing on the Sci-tech Innovation Board and became the first Chinese gene therapy CDMO stock. The company focuses on CRO services for plasmids, nucleic acids (mRNA), viruses, and cell therapy drugs, as well as CDMO and CMO services. The company has nearly 100,000 square meters of R&D, testing, and production workshops for gene and cell therapy drugs, and its production scale will enter the first tier of the global CGT industry. In the CGT field, it has obtained more than 20 clinical approval documents and has experience in multiple projects that have been reported in both China and the US.
01
Consultation for Participation
Registration Consultation | Business Cooperation | Media Cooperation
Contact Person:
Ms. Li 18917935734 (same WeChat)
Ms. Bai 18019047843 (same WeChat)
02
Highlights from the Previous Session
